Key result
High-dose finerenone significantly reduced proteinuria in patients with diabetic kidney disease compared to placebo (MD -0.31) and was identified as the optimal alternative among MRAs.
Why the study?
Diabetic kidney disease is a major cause of ESRD, and the comparative efficacy and safety of different MRAs needed evaluation.
Do mineralocorticoid receptor antagonists improve UACR, eGFR, and SBP in patients with diabetic kidney disease?
Meta-Analysis (n=15,492)
Do mineralocorticoid receptor antagonists improve UACR, eGFR, and SBP in patients with diabetic kidney disease?
Effect estimate: MD -0.31 (95% CI -0.52, -0.11)
In a network meta-analysis of patients with diabetic kidney disease, 20 mg of finerenone demonstrated superiority among MRAs in reducing proteinuria and maintaining kidney function, despite an increased risk of hyperkalemia.
Supports finerenone as preferred MRA for proteinuria reduction in diabetic kidney disease; extends network evidence guiding MRA selection despite hyperkalemia risk.
Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this network meta-analysis by performing a systematic search in PubMed, MEDLINE, EMBASE, Web of Science, the Cochrane Library, and Clinicaltrials.gov . A total of 12 randomized clinical trials with 15,492 patients applying various types of MRAs covering spironolactone, eplerenone, finerenone, esaxerenone, and apararenone were included. The efficacy outcomes were the ratio of urine albumin creatine ratio (UACR) at posttreatment vs. at baseline, change in posttreatment estimated glomerular filtration (eGFR) vs. at baseline, and change in posttreatment systolic blood pressure (SBP) vs. at baseline. The safety outcome was the number of patients suffering from hyperkalemia. High-dose finerenone (MD −0.31, 95% CI: −0.52, −0.11), esaxerenone (MD −0.54, 95% CI: −0.72, −0.30), and apararenone (MD −0.63, 95% CI: −0.90, −0.35) were associated with a superior reduction in proteinuria in patients with DKD. Regarding the change in eGFR, the results of all drugs were similar, and finerenone may have potential superiority in protecting the kidney. Compared with placebo, none of the treatments was associated with a higher probability of controlling systolic blood pressure during treatment. Moreover, spironolactone, esaxerenone, and 20 mg of finerenone presented a higher risk of hyperkalemia. This Bayesian network meta-analysis was the first to explore the optimal alternative among MRAs in the treatment of DKD and revealed the superiority of 20 mg of finerenone among MRAs in treating DKD. Systematic Review Registration: PROSPERO, identifier (CRD42022313826)
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) conducted a meta-analysis in Diabetic kidney disease (DKD) (n=15,492). Mineralocorticoid receptor antagonists (finerenone, esaxerenone, apararenone, spironolactone, eplerenone) vs. Placebo was evaluated on Ratio of urine albumin creatine ratio (UACR) at posttreatment vs. at baseline (MD -0.31, 95% CI -0.52, -0.11). High-dose finerenone significantly reduced proteinuria in patients with diabetic kidney disease compared to placebo (MD -0.31) and was identified as the optimal alternative among MRAs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: